Low-dose erythromycin in pediatrics: Formulation and stability of 20 mg hard gelatin capsules

Patrick Thevin, Christophe Curti, Alexandre Benech, Christophe Jean, Edouard Lamy, Caroline Castera Ducros, Nicolas Primas, Pierre Bertault-Peres and Patrice Vanelle

PLOS ONE, 2023, vol. 18, issue 2, 1-9

Abstract: Objective: Erythromycin is a macrolide antibiotic that is also prescribed off-label in premature neonates as a prokinetic agent. There is no oral formulation with dosage and/or excipients adapted for these high-risk patients. Methods: Clinical studies of erythromycin as a prokinetic agent were reviewed. Capsules of 20 milligrams of erythromycin were compounded with microcrystalline cellulose. Erythromycin capsules were analyzed using the chromatographic method described in the United States Pharmacopoeia which was found to be stability-indicating. The stability of 20 mg erythromycin capsules stored protected from light at room temperature was studied for one year. Results: 20 mg erythromycin capsules have a beyond use date not lower than one year. Conclusion: 20 milligrams erythromycin capsules can be compounded in batches of 300 unities in hospital pharmacy with a beyond-use-date of one year at ambient temperature protected from light.

Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0282164 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 82164&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0282164

DOI: 10.1371/journal.pone.0282164

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().